Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation

Sidharth Mahapatra, Clifford C. Chin, Andrei Iagaru, Amy Heerema-Mckenney, Clare J. Twist

Research output: Contribution to journalArticle

2 Scopus citations


Post-transplant lymphoproliferative disorder (PTLD) describes a spectrum of conditions with highest incidence in the first year post-solid organ transplant in pediatric patients. Central nervous system (CNS) involvement with PTLD carries high mortality risk with no consensus on optimal therapeutic regimen. We present the case of a 7-year old heart transplant patient diagnosed with widespread monomorphic, CD20+, Epstein-Barr virus-positive PTLD, including CNS involvement. In addition to immunosuppression reduction and rituximab, she was treated with multiagent systemic and intrathecal chemotherapy. She achieved a prompt and complete clinical and radiologic remission, which has been sustained for over 46 months since diagnosis.

Original languageEnglish (US)
Pages (from-to)2107-2109
Number of pages3
JournalPediatric Blood and Cancer
Issue number11
StatePublished - Nov 1 2014



  • Central nervous system post-transplant lymphoproliferative disorder (CNS PTLD)
  • Chemotherapy
  • Epstein-Barr virus (EBV)
  • Heart transplant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this